Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

NCT07055477 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07055477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Suspended
Start date
September 29, 2025
Completion date
June 1, 2044
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, cutaneous t-cell lymphoma, enteropathy associated t-cell lymphoma, hepatosplenic t-cell lymphoma, monomorphic epithelialtropic intestinal lymphoma, mycosis fungoides, peripheral t-cell lymphoma, relapsed and/or refractory mature t cell malignancy, subacute panniculitis-like t-cell lymphoma